Matthew Carabasi

2.7k citations

47 papers · 1.7k indexed · 1 hit paper · h-index 15

Co-authors: Esperanza B. Papadopoulos Alfred P. Gillio Hugo Castro‐Malaspina James W. Young Nancy A. Kernan Stephen Mackinnon Farid Boulad Barrett H. Childs
Topics: Hematopoietic Stem Cell Transplantation (25 papers)Immune Cell Function and Interaction (14 papers)Acute Myeloid Leukemia Research (12 papers)
Cited by: Hematology Oncology Immunology
Journals: New England Journal of Medicine Journal of Clinical Oncology Blood
Partner nations: United States Sweden Canada

In The Last Decade

Matthew Carabasi

41 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation

1994 809 citations Esperanza B. Papadopoulos, Marc Ladanyi et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Matthew Carabasi

Since Specialization

Citations

This map shows the geographic impact of Matthew Carabasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Carabasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Carabasi more than expected).

Fields of papers citing papers by Matthew Carabasi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Carabasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Carabasi. The network helps show where Matthew Carabasi may publish in the future.

Co-authorship network of co-authors of Matthew Carabasi

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Carabasi. A scholar is included among the top collaborators of Matthew Carabasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Carabasi. Matthew Carabasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia 2023 ·Cancers ·Neil Palmisiano,Grace R. Jeschke,Lindsay Wilde,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Dolores Grosso,Thomas R. Klumpp,(unknown),John L. Wagner,Martin Carroll,Alexander E. Perl,Margaret Kasner	0
2	A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation 2022 ·Transplantation and Cellular Therapy ·Dolores Grosso,Benjamin E. Leiby,Lindsay Wilde,Matthew Carabasi,Joanne Filicko-O’Hara,(unknown),John L. Wagner,(unknown),Önder Alpdoğan,Adam Binder,Margaret Kasner,(unknown),Thomas R. Klumpp,(unknown),Neil Palmisiano,Pierluigi Porcu,Usama Gergis,Neal Flomenberg	3
3	Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies 2022 ·Bone Marrow Transplantation ·(unknown),Usama Gergis,John L. Wagner,Matthew Carabasi,Joanne Filicko-O’Hara,(unknown),Thomas R. Klumpp,Pierluigi Porcu,Neal Flomenberg,Dolores Grosso	3
4	Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes 2020 ·Biology of Blood and Marrow Transplantation ·Dolores Grosso,Matthew Carabasi,Joanne Filicko-O’Hara,John L. Wagner,(unknown),Michael Sun,Beth Colombe,Wenyin Shi,Maria Werner‐Wasik,(unknown),Önder Alpdoğan,Adam Binder,Margaret Kasner,Thomas R. Klumpp,Ubaldo Martinez‐Outschoorn,Neil Palmisiano,Lindsay Wilde,Pierluigi Porcu,Usama Gergis,Neal Flomenberg	3
5	COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience 2020 ·Blood ·Lindsay Wilde,Adam Binder,Matthew Carabasi,Joanne Filicko-O’Hara,John L. Wagner,Önder Alpdoğan,Margaret Kasner,Thomas R. Klumpp,Ubaldo Martinez‐Outschoorn,Neil Palmisiano,(unknown),Dolores Grosso,Michael Millenson,Amy R. MacKenzie,(unknown),Neal Flomenberg,Pierluigi Porcu,Usama Gergis	1
6	An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation 2020 ·Transplantation and Cellular Therapy ·(unknown),Benjamin E. Leiby,(unknown),Amy Leader,(unknown),(unknown),(unknown),Matthew Carabasi,Joanne Filicko-O’Hara,(unknown),John L. Wagner,Usama Gergis,Neal Flomenberg,Dolores Grosso	4
7	Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters 2019 ·Biology of Blood and Marrow Transplantation ·Jason Chen,(unknown),Tingting Zhan,Sherilyn A. Tuazon,Neeraj Saini,(unknown),Joanne Filicko-O’Hara,Thomas R. Klumpp,Margaret Kasner,Matthew Carabasi,Pierluigi Porcu,John L. Wagner	6
8	Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition 2018 ·Investigational New Drugs ·Margaret Kasner,Rosemarie Mick,Grace R. Jeschke,Matthew Carabasi,Joanne Filicko-O’Hara,Neal Flomenberg,Noelle V. Frey,Elizabeth O. Hexner,Selina M. Luger,Alison W. Loren,James K. Mangan,John L. Wagner,Mark A. Weiss,Martin Carroll,Alexander E. Perl	17
9	Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT) 2017 ·Blood ·Jason Chen,(unknown),John L. Wagner,Michael Sun,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Sameh Gaballa,Margaret Kasner,Thomas R. Klumpp,Neil Palmisiano,Ubaldo Martinez‐Outschoorn,Pierluigi Porcu,Neal Flomenberg,Dolores Grosso	1
10	Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome 2017 ·Bone Marrow Transplantation ·Praveen Ramakrishnan Geethakumari,Benjamin E. Leiby,(unknown),(unknown),Matthew Carabasi,Joanne Filicko-O’Hara,Sameh Gaballa,Margaret Kasner,Thomas R. Klumpp,Ubaldo Martinez‐Outschoorn,Neil Palmisiano,John L. Wagner,Pierluigi Porcu,Neal Flomenberg,Dolores Grosso	3
11	Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization 2017 ·Bone Marrow Transplantation ·Dolores Grosso,Eugene H. Johnson,Beth Colombe,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Sameh Gaballa,Margaret Kasner,Thomas R. Klumpp,Ubaldo Martinez‐Outschoorn,John L. Wagner,Mark A. Weiss,(unknown),Neal Flomenberg	11
12	A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation 2015 ·Biology of Blood and Marrow Transplantation ·Sameh Gaballa,Neil Palmisiano,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Margaret Kasner,Walter K. Kraft,Benjamin E. Leiby,Ubaldo Martinez‐Outschoorn,(unknown),Barbara Pro,(unknown),Manish Sharma,John L. Wagner,Mark A. Weiss,Neal Flomenberg,Dolores Grosso	21
13	A Two-Step Approach to Myeloablative Haploidentical Transplantation: Low Nonrelapse Mortality and High Survival Confirmed in Patients with Earlier Stage Disease 2014 ·Biology of Blood and Marrow Transplantation ·Dolores Grosso,Sameh Gaballa,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Margaret Kasner,Ubaldo Martinez‐Outschoorn,John L. Wagner,(unknown),(unknown),Inna Chervoneva,Beth Colombe,(unknown),Phyllis Flomenberg,Barbara Pro,Manish Sharma,Wenyin Shi,Mark A. Weiss,Neal Flomenberg	31
14	Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? 2011 ·Journal of Clinical Oncology ·John Horan,Brent R. Logan,Afiba Manza‐A. Agovi,Hillard M. Lazarus,(unknown),Karen K. Ballen,Christopher Bredeson,Matthew Carabasi,Vikas Gupta,Gregory A. Hale,H. Jean Khoury,Mark Juckett,Mark R. Litzow,Rodrigo Martino,Philip L. McCarthy,Franklin O. Smith,J. Douglas Rizzo,Marcelo C. Pasquini	133
15	Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen 2006 ·Biology of Blood and Marrow Transplantation ·Charu Aggarwal,Sameer Gupta,William P. Vaughan,Gene Saylors,Donna Salzman,(unknown),(unknown),Arabella B. Tilden,Matthew Carabasi	40
16	Clinical Protocol: A Phase I-II Trial to Examine the Toxicity of CMV- and EBV-Specific Cytotoxic T Lymphocytes When Used for Prophylaxis against EBV and CMV Disease in Recipients of CD34-Selected/T Cell-Depleted Stem Cell Transplants 2000 ·Human Gene Therapy ·(unknown),Qingsong Sun,Robert L. Burton,Arabella B. Tilden,William P. Vaughan,Matthew Carabasi,Donna Salzman,(unknown)	38
17	A Novel Gene Therapy Strategy for Elimination of Prostate Carcinoma Cells from Human Bone Marrow 1997 ·Human Gene Therapy ·Myung‐Hee Kim,M. Wright,Jessy S. Deshane,Mary Ann Accavitti,Arabella B. Tilden,Mansoor N. Saleh,William P. Vaughan,Matthew Carabasi,Miriam D. Rogers,Richard D. Hockett,William E. Grizzle,David T. Curiel	25
18	Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantationbreakdown → 1994 ·New England Journal of Medicine ·Esperanza B. Papadopoulos,Marc Ladanyi,David Emanuel,Stephen Mackinnon,Farid Boulad,Matthew Carabasi,Hugo Castro‐Malaspina,Barrett H. Childs,Alfred P. Gillio,(unknown),James W. Young,Nancy A. Kernan,Richard J. O’Reilly	809
19	New technology for the depletion of T cells from soybean lectin agglutinated, HLA-matched bone marrow grafts for leukemia: initial laboratory and clinical results. 1992 ·PubMed ·N H Collins,Matthew Carabasi,(unknown),(unknown),James W. Young,Hugo Castro‐Malaspina,Neal Flomenberg,Esperanza B. Papadopoulos,David Emanuel,Alfred P. Gillio	7
20	Activation of peripheral CD8⁺ T lymphocytes via CD28 plus CD2: Evidence for IL‐2 gene transcription mediated by CD28 activation 1991 ·Tissue Antigens ·Matthew Carabasi,James P. Di Santo,Soo Young Yang,Bo Dupont	3

About Matthew Carabasi

Matthew Carabasi is a scholar working on Hematology, Transplantation and Immunology, having authored 47 papers that have together received 1.7k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (25 papers), Immune Cell Function and Interaction (14 papers) and Acute Myeloid Leukemia Research (12 papers). The work is most often cited by research in Hematology (682 citations), Oncology (910 citations) and Immunology (549 citations). Matthew Carabasi has collaborated with scholars based in United States, Sweden and Canada. Frequent co-authors include Esperanza B. Papadopoulos, Alfred P. Gillio, Hugo Castro‐Malaspina, James W. Young, Nancy A. Kernan, Stephen Mackinnon, Farid Boulad, Barrett H. Childs, David Emanuel and Marc Ladanyi. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact